###begin article-title 0
###xml 70 75 <span type="species:ncbi:10090">Mouse</span>
Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy
###end article-title 0
###begin p 1
Conceived and designed the experiments: MF AB OC. Performed the experiments: MF JV JG JPD FS NH FC CJ HAO ST RD OC. Analyzed the data: MF DL FPD CGZ MH AB OC. Contributed reagents/materials/analysis tools: KEP HL CH CD CCS PJK. Wrote the paper: MF JV OC.
###end p 1
###begin p 2
###xml 132 136 128 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
In synucleinopathies, including Parkinson's disease, partially ubiquitylated alpha-synuclein species phosphorylated on serine 129 (PS129-alpha-synuclein) accumulate abnormally. Parkin, an ubiquitin-protein ligase that is dysfunctional in autosomal recessive parkinsonism, protects against alpha-synuclein-mediated toxicity in various models.
###end p 2
###begin p 3
###xml 427 431 423 427 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 457 460 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 621 625 609 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 763 767 747 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 889 893 869 873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1003 1007 979 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 50 55 <span type="species:ncbi:10090">mouse</span>
###xml 218 222 <span type="species:ncbi:10090">mice</span>
###xml 946 950 <span type="species:ncbi:10090">mice</span>
###xml 1309 1314 <span type="species:ncbi:9606">human</span>
###xml 1378 1382 <span type="species:ncbi:10090">mice</span>
We analyzed the effects of Parkin deficiency in a mouse model of synucleinopathy to explore the possibility that Parkin and alpha-synuclein act in the same biochemical pathway. Whether or not Parkin was present, these mice developed an age-dependent neurodegenerative disorder preceded by a progressive decline in performance in tasks predictive of sensorimotor dysfunction. The symptoms were accompanied by the deposition of PS129-alpha-synuclein but not PS87-alpha-synuclein in neuronal cell bodies and neuritic processes throughout the brainstem and the spinal cord; activation of caspase 9 was observed in 5% of the PS129-alpha-synuclein-positive neurons. As in Lewy bodies, ubiquitin-immunoreactivity, albeit less abundant, was invariably co-localized with PS129-alpha-synuclein. During late disease stages, the disease-specific neuropathological features revealed by ubiquitin- and PS129-alpha-synuclein-specific antibodies were similar in mice with or without Parkin. However, the proportion of PS129-alpha-synuclein-immunoreactive neuronal cell bodies and neurites co-stained for ubiquitin was lower in the absence than in the presence of Parkin, suggesting less advanced synucleinopathy. Moreover, sensorimotor impairment and manifestation of the neurodegenerative phenotype due to overproduction of human alpha-synuclein were significantly delayed in Parkin-deficient mice.
###end p 3
###begin p 4
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
These findings raise the possibility that effective compensatory mechanisms modulate the phenotypic expression of disease in parkin-related parkinsonism.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 570 573 562 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Fujiwara1">[1]</xref>
###xml 575 578 567 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Anderson1">[2]</xref>
###xml 689 692 677 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Anderson1">[2]</xref>
###xml 693 696 681 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Sampathu1">[4]</xref>
###xml 780 784 764 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 844 847 824 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Anderson1">[2]</xref>
###xml 908 912 884 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA</italic>
###xml 993 997 969 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA</italic>
###xml 1067 1070 1043 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Singleton1">[5]</xref>
###xml 1132 1136 1108 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA</italic>
###xml 1185 1188 1161 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Ibanez1">[6]</xref>
###xml 1190 1193 1166 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Singleton2">[7]</xref>
###xml 1213 1217 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA</italic>
###xml 1321 1324 1297 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Miller1">[8]</xref>
###xml 1147 1155 <span type="species:ncbi:9606">patients</span>
alpha-Synuclein- and ubiquitin-immunoreactive protein inclusions in neuronal cell bodies and processes (Lewy bodies, LBs; Lewy neurites) or in glial cells are pathological markers of a subset of neurodegenerative diseases referred to as synucleinopathies; these diseases include Parkinson's disease (PD), dementia with LBs and other LB diseases, and multiple system atrophy. Phosphorylation of serine 129 is a widespread alpha-synuclein modification in LBs, whereas serine 87, found to be constitutively phosphorylated in cell lines, is not modified in these inclusions [1], [2]. A fraction of alpha-synuclein is covalently modified by one to three ubiquitin molecules in these inclusions [2]-[4]; there is biochemical evidence that alpha-synuclein phosphorylated on serine 129 (PS129-alpha-synuclein) is the major substrate for ubiquitylation [2]. Three rare missense mutations in the alpha-synuclein gene, SCNA, and more frequently duplications or triplications of genomic regions including SCNA are responsible for parkinsonism with autosomal dominant inheritance [5]. The severity of the phenotype correlates with the number of SCNA copies in patients with genomic multiplications [6], [7], and supernumerary SCNA alleles are associated with increased protein load in both the blood and brain of affected individuals [8]. Thus, the pathogenesis of these familial parkinsonian syndromes appears to be a consequence of the overproduction of normal alpha-synuclein.
###end p 6
###begin p 7
###xml 133 136 129 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Giasson1">[9]</xref>
###xml 137 141 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 486 489 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Giasson1">[9]</xref>
###xml 491 495 479 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-vanderPutten1">[10]</xref>
###xml 497 501 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 503 507 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Martin1">[15]</xref>
###xml 677 685 657 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 791 795 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Tofaris2">[16]</xref>
###xml 848 855 828 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 143 147 <span type="species:ncbi:10090">Mice</span>
###xml 163 168 <span type="species:ncbi:9606">human</span>
###xml 547 552 <span type="species:ncbi:9606">human</span>
Overproduction of normal or mutated alpha-synuclein in invertebrate and rodent models leads to synucleinopathy and neurodegeneration [9]-[14]. Mice transgenic for human A30P or A53T alpha-synuclein develop adult-onset neurodegenerative disorders leading to progressive paralysis due to pathological alterations in brainstem and spinal cord neuronal cell bodies or axons, concomitant with the deposition of alpha-synuclein- and ubiquitin-immunoreactive material throughout these regions [9], [10], [14], [15]. Despite these striking parallels with human synucleinopathies, the molecular mechanisms underlying alpha-synuclein toxicity remain unclear. alpha-Synuclein aggregation in vitro is a multi-step process involving the formation of oligomers, protofibrils and insoluble amyloid fibrils [16]. How, and in which order, this process is modulated in vivo by phosphorylation, ubiquitylation and possibly other modifications is not known, and there is debate concerning the contributions of the various molecular species to neurodegeneration.
###end p 7
###begin p 8
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Corti1">[17]</xref>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Klein1">[18]</xref>
###xml 372 376 372 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Lohmann1">[19]</xref>
###xml 426 432 426 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Smith1">[20]</xref>
###xml 641 645 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Hampe1">[26]</xref>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Pawlyk1">[27]</xref>
###xml 870 874 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Chung1">[29]</xref>
###xml 916 922 912 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1015 1021 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1041 1052 1037 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post mortem</italic>
###xml 1193 1197 1185 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Cookson1">[30]</xref>
###xml 1257 1261 1245 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Chung2">[31]</xref>
###xml 1450 1454 1434 1438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Yang1">[32]</xref>
###xml 1455 1459 1439 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-LoBianco1">[35]</xref>
###xml 1988 1994 1956 1962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 1549 1564 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1575 1580 <span type="species:ncbi:9606">human</span>
###xml 1657 1661 <span type="species:ncbi:10090">mice</span>
###xml 1670 1674 <span type="species:ncbi:10090">mice</span>
Parkin is an E3 ubiquitin-protein ligase that is abnormal in many cases of autosomal recessive parkinsonism [17]. Carriers of parkin mutations have a more favourable disease course compared to sporadic PD patients: although onset is generally earlier, disease progression is significantly slower and the response to dopaminergic treatment better than in sporadic PD [18], [19]. Loss of Parkin function, due to disease-causing parkin mutations, may impair proteasomal degradation of toxic substrates, but may also compromise non-proteolytic ubiquitin-dependent pathways related to protein aggregation, protein sorting or cell signalling [20]-[26]; partial loss of Parkin function, through age-related or pathological alterations in its biochemical properties, may also contribute to neurodegeneration associated with sporadic PD and possibly other synucleinopathies [27]-[29]. Whether alpha-synuclein plays a role in parkin-related parkinsonism is unclear. Of eight PD cases with homozygous or compound heterozygous parkin mutations analyzed post mortem, only three had typical LBs and even here in small numbers, and only one had basophilic alpha-synuclein-immunopositive dendritic inclusions [30]. Although native alpha-synuclein is not a Parkin substrate [31], overproduction of Parkin provided protection in a variety of models associated with the short-term accumulation of alpha-synuclein, suggesting that these proteins are functionally linked [32]-[35]. We explored this possibility further, by evaluating the effects of Parkin deficiency in transgenic mice producing human A30P alpha-synuclein under the control of the Thy1 promoter (hA30Palpha-syn mice). These mice develop alpha-synuclein-dependent neurodegeneration over a mean period of twenty months. Surprisingly, Parkin deficiency significantly retarded disease manifestation in this model. These findings suggest that loss of Parkin function may act as a beneficial modifier of alpha-synucleinopathy in slowly progressing parkin-related parkinsonian syndromes.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 101 105 <span type="species:ncbi:10090">mice</span>
Parkin-deficiency delays progression of the neurodegenerative phenotype in transgenic hA30Palpha-syn mice
###end title 10
###begin p 11
###xml 205 211 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 233 243 229 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin &#8722;/&#8722;</italic>
###xml 245 249 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Itier1">[36]</xref>
###xml 274 278 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 280 284 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Kahle1">[37]</xref>
###xml 286 295 278 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g001">Figure 1A</xref>
###xml 309 319 301 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin &#8722;/&#8722;</italic>
###xml 720 726 708 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 828 837 812 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g001">Figure 1B</xref>
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 192 197 <span type="species:ncbi:10090">mouse</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 551 555 <span type="species:ncbi:10090">mice</span>
A mouse model transgenic for human A30P alpha-synuclein and deficient for Parkin was generated through a breeding strategy aimed at minimising strain effects, using two previously established mouse lines: parkin exon 3-deleted mice (parkin -/-) [36] and hA30Palpha-syn mice [14], [37] (Figure 1A). Homozygous parkin -/- mice were bred with homozygous hA30Palpha-syn mice. The double heterozygous generation was intercrossed to generate littermates of the nine expected genotypes in proportions consistent with Mendelian inheritance. Double homozygous mice and their age-matched littermates of wild-type or single homozygous, parental genotypes were kept for subsequent analyses. Appropriate expression of the endogenous parkin gene and the alpha-synuclein transgene were confirmed by western blotting with whole brain extracts (Figure 1B).
###end p 11
###begin title 12
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 33 38 <span type="species:ncbi:9606">human</span>
Generation of mice overproducing human alpha-synuclein in a Parkin-deficient background.
###end title 12
###begin p 13
###xml 43 53 43 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin &#8722;/&#8722;</italic>
###xml 431 437 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
(A) Breeding strategy. Parental homozygous parkin -/- and hA30Palpha-syn +/+ mice were intercrossed. The breeding of the double heterozygous mice (F1) led to the generation of littermates of the nine expected genotypes, four of which, highlighted by the surrounding frames, were used for subsequent analyses. (B) Representative western blot analysis of brain extracts of 17 months-old mice showing the expression of the endogenous parkin gene and of the hA30Palpha-syn transgene, normalized to actin levels.
###end p 13
###begin p 14
###xml 378 382 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 475 479 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 481 491 477 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s001">Results S1</xref>
###xml 493 502 489 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s006">Figure S2</xref>
###xml 507 515 503 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s004">Table S1</xref>
###xml 613 623 605 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s001">Results S1</xref>
###xml 625 635 617 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s005">Figure S1B</xref>
###xml 809 815 797 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 993 1001 981 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g002">Figure 2</xref>
###xml 1099 1103 1087 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Barneoud1">[38]</xref>
###xml 1190 1194 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Freichel1">[39]</xref>
###xml 1344 1353 1328 1337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g002">Figure 2A</xref>
###xml 1394 1400 1378 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1702 1711 1682 1691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g002">Figure 2A</xref>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
###xml 775 779 <span type="species:ncbi:10090">mice</span>
###xml 1185 1189 <span type="species:ncbi:10090">mice</span>
###xml 1405 1409 <span type="species:ncbi:10090">mice</span>
###xml 1590 1594 <span type="species:ncbi:10090">mice</span>
As expected, adult transgenic hA30Palpha-syn mice with or without Parkin developed a neurodegenerative phenotype with age-dependent penetrance, characterized by rapidly deteriorating motor performance, resulting in paralysis of the hindlimbs within approximately one month of the appearance of the first observable clinical signs (unsteady gait, hindlimb weakness and dragging) [14]. These symptoms developed in the absence of degeneration of the nigral dopaminergic neurons [14] (Results S1, Figure S2 and Table S1), a neuronal population in which human alpha-synuclein was not detected by immunohistochemistry (Results S1, Figure S1B). We investigated whether Parkin deficiency affected the incidence and the progression of this neurodegenerative phenotype: hA30Palpha-syn mice with or without a functional parkin gene and their littermates of wild-type and parental genotypes were followed from 9 months of age until death to unravel potential disease-predictive changes in motor function (Figure 2). Every week, we tested the hindlimb extension reflex, which is altered by motor neuron diseases [38], and performance on a rotarod, which is progressively impaired in hA30Palpha-syn mice [39]. The mean performance in each task was plotted against age for each genotype and the trends were analysed using a second order polynomial curve fit (Figure 2A). The mean performance of wild-type and parkin -/- mice in both tasks was similar and remained constant throughout the testing period; in contrast, a progressive, disease-predictive decline in performance was observed in hA30Palpha-syn mice. In addition, the decline in performance of both tasks was significantly delayed in the absence of Parkin (Figure 2A).
###end p 14
###begin title 15
###xml 97 101 <span type="species:ncbi:10090">mice</span>
Progression of the neurodegenerative phenotype is delayed by Parkin deficiency in hA30Palpha-syn mice.
###end title 15
###begin p 16
###xml 333 339 333 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 349 350 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 388 389 388 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 522 523 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
(A) Motor function was assessed by evaluating the hindlimb extension reflex (upper graph) and rotarod performance (lower graph). Mean performance is plotted against age for each genotype and the curvature and slope of parabolic regressions were analysed statistically (n = 10-16). #, slope and curvature different from wild-type and parkin -/- with p<0.0001; *, different curvatures with p<0.05. (B) Age-dependent penetrance of the neurodegenerative phenotype in hA30Palpha-syn mice with or without Parkin (n = 12-14). *, p<0.01 (Kaplan-Meier analysis).
###end p 16
###begin p 17
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 411 420 403 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g002">Figure 2B</xref>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
###xml 141 146 <span type="species:ncbi:9606">human</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
Consistent with delayed motor impairment in parkin -/- mice, the manifestation of the neurodegenerative disorder caused by overproduction of human alpha-synuclein - here defined as the inability to perform the rotarod task (performance = 0) - was significantly retarded in the absence of Parkin, as illustrated by Kaplan-Meier curves representing the age-dependent penetrance of disease in hA30Palpha-syn mice (Figure 2B).
###end p 17
###begin title 18
###xml 31 35 31 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 61 64 57 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 126 141 <span type="species:ncbi:10090">transgenic mice</span>
Accumulation of ubiquitin and PS129-alpha-synuclein but not PS87-alpha-synuclein is associated with disease in hA30Palpha-syn transgenic mice
###end title 18
###begin p 19
###xml 41 45 37 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 67 70 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 238 247 222 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3A</xref>
###xml 354 363 334 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3B</xref>
###xml 542 551 522 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3C</xref>
###xml 555 558 535 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 703 712 679 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3B</xref>
###xml 728 737 704 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3C</xref>
###xml 746 750 722 726 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 902 911 874 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3B</xref>
###xml 926 935 898 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3C</xref>
###xml 962 966 934 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1246 1250 1214 1218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1342 1357 1306 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3D and E</xref>
###xml 1484 1490 1444 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1583 1592 1543 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g003">Figure 3F</xref>
###xml 17 22 <span type="species:ncbi:9606">human</span>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
###xml 674 678 <span type="species:ncbi:10090">mice</span>
###xml 778 782 <span type="species:ncbi:10090">mice</span>
###xml 1018 1022 <span type="species:ncbi:10090">mice</span>
###xml 1171 1175 <span type="species:ncbi:10090">mice</span>
###xml 1336 1340 <span type="species:ncbi:10090">mice</span>
###xml 1461 1465 <span type="species:ncbi:10090">mice</span>
We assayed total human alpha-synuclein, PS129-alpha-synuclein and PS87-alpha-synuclein in aged healthy and end-stage symptomatic hA30Palpha-syn mice with and without Parkin with antibodies recognizing specifically each of these proteins (Figure 3A). Total human alpha-synuclein was found in the buffer-soluble (TBS) and -insoluble (SDS) brain fractions (Figure 3B, upper panel); it was for the most part soluble and its relative solubility did not change with the appearance of symptoms and was similar in the presence and absence of Parkin (Figure 3C). PS87-alpha-synuclein was only found in the TBS fraction, and the amounts found were similar for healthy and symptomatic mice with or without Parkin (Figure 3B, middle panel, Figure 3C). Most PS129-alpha-synuclein in healthy mice was soluble, with approximately 10% of the protein being buffer-insoluble, both in the presence and absence of Parkin (Figure 3B, lower panel, Figure 3C). In contrast, insoluble PS129-alpha-synuclein species accumulated in symptomatic mice, with approximately 60% of the protein found in the SDS fraction whether Parkin was present or not (p<0.001 between symptomatic and non symptomatic mice). In this fraction, long exposure times revealed variable amounts of PS129-alpha-synuclein species with retarded electrophoretic mobilities only in symptomatic mice (Figure 3D and E). Soluble Parkin was readily detected in the TBS fractions from healthy and symptomatic hA30Palpha-syn mice with a functional parkin gene. In contrast, it was not observed in the SDS fractions even after long exposure times (Figure 3F).
###end p 19
###begin title 20
###xml 19 23 19 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 49 52 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 144 148 <span type="species:ncbi:10090">mice</span>
The solubility of PS129-alpha-synuclein but not PS87-alpha-synuclein species is decreased in the brains of end-stage symptomatic hA30Palpha-syn mice.
###end title 20
###begin p 21
###xml 389 392 381 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 404 408 396 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 495 502 479 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87,129</sup>
###xml 529 537 509 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 581 585 561 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Paleologou1">[42]</xref>
###xml 662 665 638 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 711 719 683 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 773 776 741 744 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 839 843 799 803 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 878 882 834 838 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 925 929 877 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 954 957 902 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 1044 1047 984 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 1069 1073 1005 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1316 1319 1244 1247 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 1341 1345 1265 1269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1738 1742 1650 1654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1892 1893 1800 1801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1942 1946 1850 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 2167 2171 2071 2075 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 94 99 <span type="species:ncbi:9606">human</span>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
###xml 1233 1237 <span type="species:ncbi:10090">mice</span>
###xml 1292 1297 <span type="species:ncbi:9606">human</span>
###xml 1423 1427 <span type="species:ncbi:10090">mice</span>
###xml 1825 1829 <span type="species:ncbi:10090">mice</span>
###xml 1883 1887 <span type="species:ncbi:10090">mice</span>
###xml 2088 2092 <span type="species:ncbi:10090">mice</span>
###xml 2269 2273 <span type="species:ncbi:10090">mice</span>
###xml 2413 2418 <span type="species:ncbi:10090">mouse</span>
###xml 2484 2488 <span type="species:ncbi:10090">mice</span>
###xml 2548 2553 <span type="species:ncbi:10090">mouse</span>
###xml 2666 2670 <span type="species:ncbi:10090">mice</span>
(A) Representative western blot using protein-specific antibodies illustrating recognition of human alpha-synuclein and its isoforms phosphorylated at serine 87 or 129, in the TBS-soluble brain fraction of a symptomatic transgenic hA30Palpha-syn mouse. These proteins were not detected in the TBS- or SDS-soluble brain fractions of an aged wild-type control animal (left panel). The anti-PS87- and anti-PS129-alpha-synuclein antibodies detected specifically normal recombinant alpha-synuclein (PS87,129alpha-syn), phosphorylated in vitro by casein kinase 1 as described previously [42], but not the non phosphorylated protein (alpha-syn). As expected, the anti-PS87-alpha-synuclein antibody also recognized the in vitro-phosphorylated S129A alpha-synuclein variant (S129A PS87alpha-syn), but not phosphorylated S87A alpha-synuclein (S87A PS129alpha-syn). In contrast, the anti-PS129-alpha-synuclein antibody recognized S87A PS129alpha-syn but not S129A PS87alpha-syn. (B) Representative western blots illustrating alpha-synuclein (top panel), PS87-alpha-synuclein and PS129-alpha-synuclein (middle and bottom panels) protein abundance in TBS-soluble and -insoluble (SDS) brain fractions from symptomatic (S) and non symptomatic (ns) mice with and without Parkin. (C) Quantitative analysis of human alpha-synuclein, PS87-alpha-synuclein and PS129-alpha-synuclein solubility in symptomatic and non symptomatic hA30Palpha-syn mice with (ns: n = 4; S: n = 13-8) and without (ns: n = 4; S: n = 11-8) Parkin. The relative protein amount was defined as the ratio between the amount of protein normalized to alpha-tubulin in the SDS fraction, and the total amount of protein normalized to -tubulin in the SDS and TBS fractions. The abundance of PS129-alpha-synuclein in the SDS brain fraction was significantly higher in symptomatic mice in the presence or absence of Parkin than in healthy mice. *, p<0.01. (D) Representative western blots showing PS129-alpha-synuclein immunoreactive species with retarded electrophoretic mobility after long exposure times in the SDS fraction from symptomatic mice. (E) Quantitative analysis of the monomer (short exposure times) and the PS129-alpha-synuclein species with higher apparent molecular mass (long exposure times) in symptomatic mice with (n = 13) and without (n = 11) Parkin. (F) Western blot analysis with anti-Parkin antibodies of TBS and SDS fractions from a wild-type mouse, a representative pool of healthy and symptomatic hA30Palpha-syn mice, and a symptomatic Parkin-deficient hA30Palpha-syn control mouse. Parkin was abundant in the TBS fractions but was not detected in the SDS fractions from healthy or symptomatic mice, even after long exposure times. The asterisk indicates a non specific band recognized by anti-Parkin antibodies.
###end p 21
###begin p 22
###xml 97 101 93 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 120 123 112 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 401 411 385 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s001">Results S1</xref>
###xml 413 423 397 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s005">Figure S1A</xref>
###xml 427 430 411 414 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 566 570 546 550 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 775 787 747 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g004">Figure 4A, B</xref>
###xml 792 804 764 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g005">Figure 5A, B</xref>
###xml 826 830 798 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 940 949 908 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g004">Figure 4B</xref>
###xml 1085 1095 1049 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g004">Figures 4C</xref>
###xml 1100 1102 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g005">5B</xref>
###xml 1169 1173 1133 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1259 1265 1219 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 226 230 <span type="species:ncbi:10090">mice</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 989 993 <span type="species:ncbi:10090">mice</span>
We used immunohistochemistry to study the regional distribution of total human alpha-synuclein, PS129-alpha-synuclein, PS87-alpha-synuclein and ubiquitin in the central nervous system of aged healthy and end-stage symptomatic mice with and without Parkin. Similar distributions were found for total human alpha-synuclein in the presence and absence of Parkin, whether the animals had symptoms or not (Results S1, Figure S1A). PS87-alpha-synuclein immunoreactivity was undetectable in any of the conditions studied (data not shown). In contrast, there was extensive PS129-alpha-synuclein immunoreactivity in various regions of the brainstem and the spinal cord in end-stage symptomatic hA30Palpha-syn mice with or without Parkin, but not in their non symptomatic littermates (Figure 4A, B and Figure 5A, B). The extent of the PS129-alpha-synuclein pathology was variable between animals but was similar in the presence or absence of Parkin (Figure 4B). End-stage symptomatic hA30Palpha-syn mice but not their healthy littermates also displayed variable severity of ubiquitin pathology (Figures 4C and 5B). The regional distribution of ubiquitin overlapped with that of PS129-alpha-synuclein, but was generally less extensive; it was observed regardless of the parkin genotype.
###end p 22
###begin title 23
###xml 17 21 17 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 99 103 <span type="species:ncbi:10090">mice</span>
Distribution of PS129-alpha-synuclein- and ubiquitin-immunolabelling in symptomatic hA30Palpha-syn mice.
###end title 23
###begin p 24
###xml 63 67 63 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 395 399 387 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 611 615 591 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 932 951 904 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">superior colliculus</italic>
###xml 1029 1041 1001 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">zona incerta</italic>
###xml 1076 1091 1048 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">pars reticulata</italic>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
###xml 563 568 <span type="species:ncbi:10090">mouse</span>
###xml 701 705 <span type="species:ncbi:10090">mice</span>
###xml 876 880 <span type="species:ncbi:10090">mice</span>
###xml 922 927 <span type="species:ncbi:10090">mouse</span>
(A) Schematic illustration of the distribution and density of PS129-alpha-synuclein deposits on representative brain coronal sections of symptomatic mice. Similar distributions were observed in hA30Palpha-syn mice with or without Parkin. Regions immunolabelled in most animals are indicated in red, whereas those less frequently stained are in grey. (B) Representative micrographs illustrating PS129-alpha-synuclein-immunolabelling in the brainstem (bregma -2.9) of symptomatic hA30Palpha-syn mice with and without Parkin, and in a healthy hA30Palpha-syn control mouse. Quantitative analysis of the density of PS129-alpha-synuclein-labelling in a representative region of the brainstem of symptomatic mice (n = 5 per genotype). (C) Representative micrographs illustrating typical ubiquitin-immunoreactivity in the presence or absence of Parkin in the brainstem of symptomatic mice, and of a healthy hA30Palpha-syn control mouse. 1- superior colliculus, 2- pretectal nuclei, 3- geniculate nuclei, 4- periaqueductal grey layer, 5- zona incerta, 6- ventral tegmental area, 7- SN pars reticulata, 8- cerebellar white layer, 9- lateral cerebellar nuclei, 10- vestibular nuclei, 11- cochlear nuclei 12- trigeminal nuclei, 13- pontine reticular nuclei, 14- parvicellular reticular nuclei. Scale bars indicate 200 microm.
###end p 24
###begin title 25
###xml 87 91 <span type="species:ncbi:10090">mice</span>
Parkin deficiency mitigates neuritic pathology in end-stage symptomatic hA30Palpha-syn mice.
###end title 25
###begin p 26
###xml 45 49 45 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 615 619 603 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 146 150 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
(A) Representative micrographs illustrating PS129-alpha-synuclein and ubiquitin immunoreactivities in the brainstem of hA30Palpha-syn symptomatic mice. Swollen, spherical (black arrowheads) and elongated (black arrows) neuritic profiles, thin, thread-like neurites (white arrowhead), rare compact inclusions (white arrow), and immunostaining throughout the somatodendritic compartment (stars) were observed. The two upper right micrographs correspond to a higher magnification of the regions outlined by the frames in the left micrograph. Scale bars indicate 20 microm. (B) Representative micrographs illustrating PS129-alpha-synuclein and ubiquitin immunoreactivities in the grey matter of the cervical spinal cord from hA30Palpha-syn mice with (left column) and without Parkin (right column). Note the abundance of aberrantly swollen neuritic processes (white arrows) in the presence of Parkin. Scale bar indicates 60 microm.
###end p 26
###begin title 27
###xml 66 81 <span type="species:ncbi:10090">transgenic mice</span>
Parkin deficiency mitigates ubiquitin pathology in hA30Palpha-syn transgenic mice
###end title 27
###begin p 28
###xml 14 18 14 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 361 370 353 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g005">Figure 5A</xref>
###xml 639 643 631 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 815 824 803 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g005">Figure 5B</xref>
###xml 93 97 <span type="species:ncbi:10090">mice</span>
###xml 517 521 <span type="species:ncbi:10090">mice</span>
Staining for PS129-alpha-synuclein and for ubiquitin in end-stage symptomatic hA30Palpha-syn mice with and without Parkin appeared in thin, tortuous, often short neuritic extensions; in hypertrophied, spherical or elongated neuritic profiles; throughout the somatodendritic compartment; and, only rarely, in compact cytoplasmic, nuclear or neuritic inclusions (Figure 5A). The relative frequencies of these qualitatively different categories of labelled structures differed between animals, but they were observed in mice of both genotypes at disease end-stage; in the presence of Parkin, aberrantly swollen neuritic profiles filled with PS129-alpha-synuclein- and ubiquitin-immunoreactive material tended to be more abundant that in its absence, as illustrated on spinal cord sections from representative animals (Figure 5B).
###end p 28
###begin p 29
###xml 121 125 117 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 262 271 254 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g006">Figure 6A</xref>
###xml 335 339 327 331 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 530 534 518 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 646 655 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g006">Figure 6B</xref>
###xml 766 770 746 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 895 899 871 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1001 1010 973 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g006">Figure 6A</xref>
###xml 1106 1110 1078 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1210 1214 1174 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Smith1">[20]</xref>
###xml 1241 1245 1205 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1289 1298 1249 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g006">Figure 6A</xref>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 628 632 <span type="species:ncbi:10090">mice</span>
###xml 661 665 <span type="species:ncbi:10090">mice</span>
We determined whether the ubiquitin staining observed in diseased hA30Palpha-syn mice was associated with the deposited PS129-alpha-synuclein species by double fluorescent immunolabelling of representative brain and spinal cord sections and confocal microscopy (Figure 6A, top panel). Most of the ubiquitin staining co-localized with PS129-alpha-synuclein staining (Pearson's colocalization coefficient = 0.8 in the presence and absence of Parkin). Approximately 85% of the cell bodies and 55% of the neurites immunopositive for PS129-alpha-synuclein were co-labelled with anti-ubiquitin antibodies in transgenic hA30Palpha-syn mice with Parkin (Figure 6B); in mice deficient for Parkin, only approximately 50% of the cell bodies and 35% of the neurites containing PS129-alpha-synuclein immunopositive material were also ubiquitin-positive. However, more than 90% of the pathologically swollen PS129-alpha-synuclein-positive neurites were co-labelled for ubiquitin, whether Parkin was present or not (Figure 6A, top panel). Immunoreactivity to synphilin-1, a Parkin substrate reported to co-localize with PS129-alpha-synuclein-positive inclusions when overproduced together with alpha-synuclein in cell models [20], was not associated with PS129-alpha-synuclein-positive protein deposits (Figure 6A, middle and bottom panels).
###end p 29
###begin title 30
###xml 18 22 18 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
The frequency of PS129-alpha-synuclein-positive structures immunolabelled with anti-ubiquitin antibodies is lower in the absence than presence of Parkin.
###end title 30
###begin p 31
###xml 174 178 170 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 282 286 274 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 386 390 374 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 670 674 650 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 873 874 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 112 117 <span type="species:ncbi:10090">mouse</span>
###xml 831 835 <span type="species:ncbi:10090">mice</span>
(A) Confocal scanning laser micrographs of a brainstem section from a representative symptomatic hA30Palpha-syn mouse illustrating colocalization of ubiquitin staining with PS129-alpha-synuclein-positive deposits (top panel). Note that ubiquitin was present in most of the swollen PS129-alpha-synuclein-positive neurites (arrows). Synphilin-1-immunoreactivity was not found within the PS129-alpha-synuclein-positive deposits (middle panel), whereas it was detected in nerve processes in a representative region of the cerebellum (lower panel). gr: granular cell layer; P: Purkinje cell layer; mol: molecular cell layer. Scale bars indicate 25 microm. (B) Percentage of PS129-alpha-synuclein-immunopositive neurites and cell bodies co-labelled for ubiquitin in a representative region of the brainstem of symptomatic hA30Palpha-syn mice with or without Parkin (n = 4-5). *, p<0.05.
###end p 31
###begin p 32
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 232 236 224 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 320 329 304 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g007">Figure 7A</xref>
###xml 462 470 442 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 493 502 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g007">Figure 7B</xref>
###xml 314 318 <span type="species:ncbi:10090">mice</span>
###xml 428 433 <span type="species:ncbi:9606">human</span>
We used GST pull down and in vitro ubiquitylation assays to test whether Parkin interacts directly with and ubiquitylates phosphorylated alpha-synuclein. GST-Parkin interacted with the Parkin substrate, alpha-tubulin, but not with PS129-alpha-synuclein when added to brain extracts from symptomatic hA30Palpha-syn mice (Figure 7A). In addition, GST-Parkin was unable to promote the ubiquitylation of recombinant, phosphorylated human alpha-synuclein in a purely in vitro ubiquitylation assay (Figure 7B).
###end p 32
###begin title 33
Phosphorylated alpha-synuclein is not a Parkin substrate.
###end title 33
###begin p 34
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Hampe1">[26]</xref>
###xml 218 222 210 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 341 345 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Ren1">[54]</xref>
###xml 380 384 356 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 553 561 525 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 659 664 631 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C418R</sup>
###xml 806 814 778 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 848 855 816 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87,129</sup>
###xml 1050 1054 1014 1018 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1129 1134 1089 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C418R</sup>
###xml 1403 1408 1363 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C418R</sup>
###xml 1642 1646 1602 1606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1665 1669 1621 1625 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1869 1873 1821 1825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1964 1968 1912 1916 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 168 173 <span type="species:ncbi:10090">mouse</span>
###xml 194 199 <span type="species:ncbi:9606">human</span>
Analysis of a representative GST-pull-down assay performed by incubating GST-Parkin [26] or GST with the TBS-soluble protein fraction from a symptomatic hA30Palpha-syn mouse. Antibodies against human alpha-synuclein, PS129-alpha-synuclein or alpha-tubulin were used for western blotting. GST-Parkin interacts specifically with alpha-tubulin [54], but not with alpha-synuclein or PS129-alpha-synuclein. The asterisk indicates the GST-moiety resulting from the degradation of the proteolytically unstable recombinant GST-Parkin protein. (B) Results of an in vitro ubiquitylation assay performed by incubating GST-Parkin, or the enzymatically inactive GST-ParkinC418R variant, with ubiquitin-activating enzyme, ubiquitin-conjugating enzyme, UbcH7, FLAG-tagged ubiquitin and ATP, in the presence or absence of in vitro-phosphorylated alpha-synuclein (PS87,129-alpha-syn). Once the reaction was completed, GST-Parkin was immobilized on glutathione-sepharose beads; the beads and the supernatant fraction were analyzed by western blotting with anti-FLAG, PS129-alpha-synuclein, or anti-Parkin antibodies. GST-Parkin (but not GST-ParkinC418R) promoted its own ubiquitylation in a dose-dependent manner, as demonstrated by the amounts of ubiquitylated species in the bead fraction being proportional to the amounts of GST-Parkin used for the ubiquitylation reactions. In addition, GST-Parkin (but not GST-ParkinC418R) promoted the formation of ubiquitin chains, as indicated by the presence of a ladder of regularly spaced ubiquitin-immunoreactive protein bands in the supernatant fraction. However, GST-Parkin did not promote the ubiquitylation of PS129-alpha-synuclein: PS129-alpha-synuclein-immunoreactive proteins with higher apparent molecular mass than the monomer were not detected in the supernatant fraction at any of the GST-Parkin concentrations used in the assay (PS129-alpha-syn); moreover, we did not observe any ubiquitin-immunoreactive bands specific for PS129-alpha-synuclein in the supernatant fraction (FLAG). The asterisk indicates a FLAG immunoreactive band most likely corresponding to a thioester adduct formed between the E2 enzyme UbcH7 and FLAG-tagged ubiquitin in the presence of the E1 enzyme.
###end p 34
###begin title 35
###xml 1 5 1 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 96 111 <span type="species:ncbi:10090">transgenic mice</span>
PS129alpha-synuclein-immunoreactivity is associated with caspase 9 activation in hA30Palpha-syn transgenic mice
###end title 35
###begin p 36
###xml 51 55 51 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 159 163 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Chen1">[40]</xref>
###xml 165 169 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Gorbatyuk1">[41]</xref>
###xml 170 174 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-AzeredodaSilveira1">[44]</xref>
###xml 215 219 207 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 411 420 399 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g008">Figure 8A</xref>
###xml 523 527 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-AzeredodaSilveira1">[44]</xref>
###xml 529 533 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Yamada1">[45]</xref>
###xml 609 618 593 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g008">Figure 8B</xref>
###xml 711 715 695 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 902 906 878 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1039 1043 1007 1011 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 203 207 <span type="species:ncbi:10090">mice</span>
###xml 603 607 <span type="species:ncbi:10090">mice</span>
###xml 755 770 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1156 1160 <span type="species:ncbi:10090">mice</span>
Whether there is a causative relationship between PS129-alpha-synuclein accumulation and the pathogenesis of synucleinopathies is currently a matter of debate [40], [41]-[44]. In diseased hA30Palpha-syn mice, many PS129-alpha-synuclein-positive neuronal cell bodies were abnormally shaped, with dysmorphic nuclei or aberrantly swollen cytoplasm and proximal neurites, whether or not they accumulated ubiquitin (Figure 8A). Cleaved capase 9 immunoreactivity has been reported in viral vector-based models of synucleinopathy [44], [45], so we evaluated activation of caspase 9 in end-stage hA30Palpha-syn mice (Figure 8B). Cleaved caspase 9 was found in approximately 5% of the neuronal cell bodies accumulating PS129-alpha-synuclein in the spinal cords of transgenic mice (7.4+/-1.8% with and 4.5%+/-2.2 without Parkin; p = 0.4), and in a similar proportion of cell bodies of neurons accumulating both PS129-alpha-synuclein and ubiquitin (6.3%+/-2.8 in the presence of Parkin, 6.7%+/-2.9 in its absence; p = 0.9). Importantly, deposits of PS129-alpha-synuclein were present in more than 90% of the neurons in which caspase 9 was activated in hA30Palpha-syn mice both with (92.0%+/-3.2) and without Parkin (96.0%+/-3.1; p = 0. 4).
###end p 36
###begin title 37
###xml 1 5 1 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
PS129-alpha-synuclein-immunoreactivity is associated with activation of caspase 9.
###end title 37
###begin p 38
###xml 17 21 17 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 429 433 421 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 199 203 <span type="species:ncbi:10090">mice</span>
(A) Examples of PS129-alpha-synuclein-positive neurons with abnormally shaped nuclei and dysmorphic or abnormally swollen somata and proximal dendrites in the brainstem of symptomatic hA30Palpha-syn mice. The upper and lower right micrographs correspond to a higher magnification of the regions outlined by the frames in the left micrograph. (B) Double immunofluorescent labelling showing caspase 9 activation in representative PS129-alpha-synuclein- or ubiquitin-positive neurons of the spinal cord. Scale bars indicate 30 microm in (A) and 15 microm in (B).
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 267 271 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 606 610 594 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 752 755 736 739 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 954 957 930 933 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 1160 1163 1128 1131 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 1295 1298 1255 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Anderson1">[2]</xref>
###xml 1300 1304 1260 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Waxman1">[46]</xref>
###xml 1357 1363 1317 1323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ser129</sup>
###xml 1496 1500 1452 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Chen1">[40]</xref>
###xml 1502 1506 1458 1462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Gorbatyuk1">[41]</xref>
###xml 1508 1512 1464 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Sugeno1">[43]</xref>
###xml 1514 1518 1470 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-AzeredodaSilveira1">[44]</xref>
###xml 1601 1605 1557 1561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1742 1746 1694 1698 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1896 1899 1844 1847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Anderson1">[2]</xref>
###xml 1900 1903 1848 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Sampathu1">[4]</xref>
###xml 1905 1909 1853 1857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Hasegawa1">[47]</xref>
###xml 1924 1928 1872 1876 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 119 124 <span type="species:ncbi:9606">human</span>
###xml 214 219 <span type="species:ncbi:10090">mouse</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 911 915 <span type="species:ncbi:10090">mice</span>
###xml 1049 1054 <span type="species:ncbi:10090">mouse</span>
###xml 1076 1081 <span type="species:ncbi:9606">human</span>
###xml 1133 1141 <span type="species:ncbi:9606">patients</span>
###xml 1872 1877 <span type="species:ncbi:9606">human</span>
We report an investigation of the effects of Parkin deficiency on the pathological accumulation of the A30P variant of human alpha-synuclein and the manifestation of the neurodegenerative phenotype in a transgenic mouse model of synucleinopathy (hA30Palpha-syn mice) [14]. Disease onset in hA30Palpha-syn mice was preceded by specific, progressive impairment of performance in two tasks -hindlimb extension reflex and rotarod tests- predictive of neuronal dysfunction in sensorimotor nuclei of the brainstem and the spinal cord. Disease progression was accompanied by the specific deposition of insoluble PS129-alpha-synuclein species, detected by biochemical and immunohistochemical methods throughout the brainstem and the spinal cord. In contrast, PS87-alpha-synuclein immunoreactive species readily detected in the soluble brain fractions were not deposited as insoluble material in diseased hA30Palpha-syn mice. Previous reports failed to identify PS87-alpha-synuclein-immunoreactive species by biochemical or immunohistochemical techniques in mouse models overproducing human alpha-synuclein and in brains from synucleinopathy patients, suggesting that PS87-alpha-synuclein is not involved in the physiopathology of neurodegenerative disorders associated with alpha-synuclein accumulation [2], [46]. Whether there is a causative relationship between PSer129-alpha-synuclein accumulation and the pathogenesis of synucleinopathies is a matter of controversy which still needs to be clarified [40], [41], [43], [44]. In our model, immunoreactivity to active caspase 9 was observed in 5-10% of the PS129-alpha-synuclein-positive neuronal cell bodies of the spinal cord, and was almost exclusively associated with the presence of deposited PS129-alpha-synuclein, indicating that accumulation of this protein may be a deleterious event related to neurodegeneration. As in human synucleinopathies [2]-[4], [47], some of the PS129-alpha-synuclein deposits were associated with ubiquitin, suggesting that ubiquitylation is a secondary event following protein deposition.
###end p 40
###begin p 41
###xml 160 164 160 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 640 644 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Yang1">[32]</xref>
###xml 645 649 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-LoBianco1">[35]</xref>
###xml 954 970 938 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">substantia nigra</italic>
###xml 1150 1154 1130 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-LoBianco1">[35]</xref>
###xml 1242 1246 1222 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1581 1585 1557 1561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Smith1">[20]</xref>
###xml 1587 1591 1563 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Lim1">[24]</xref>
###xml 1591 1595 1567 1571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Corti2">[48]</xref>
###xml 1736 1740 1712 1716 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1883 1891 1847 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1975 1979 1939 1943 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 449 453 <span type="species:ncbi:10090">mice</span>
###xml 617 627 <span type="species:ncbi:7227">Drosophila</span>
###xml 635 639 <span type="species:ncbi:10116">rats</span>
###xml 950 953 <span type="species:ncbi:10116">rat</span>
###xml 1795 1799 <span type="species:ncbi:10090">mice</span>
In late-stage symptomatic mice, the disease-specific neuropathological features were similar in the presence and absence of Parkin. However, the proportion of PS129-alpha-synuclein-immunoreactive deposits associated with ubiquitin was lower, indicating less advanced alpha-synucleinopathy. Moreover, in the absence of Parkin, the mean decline in sensorimotor performance and the manifestation of disease were significantly delayed in hA30Palpha-syn mice. These results are in apparent contradiction with previous studies reporting that Parkin protects against alpha-synuclein-mediated toxicity in primary neurons, in Drosophila and in rats [32]-[35]. However, Parkin was overproduced beyond physiological levels in these models. In addition, cell survival was only monitored in the short-term, raising the possibility that Parkin modulate synucleinopathy with distinct short-term and long-term effects on neuronal viability. When overproduced in the rat substantia nigra together with A30P alpha-synuclein by lentiviral vector-mediated gene transfer, Parkin protected dopaminergic neurons from degeneration six weeks after inoculation of the vectors [35]. Neuroprotection was accompanied by an increase in the proportion of neurons carrying PS129-alpha-synuclein-positive aggregates, suggesting that Parkin promotes the deposition of this protein. Other studies have shown that overproduced Parkin promotes the formation of ubiquitylated aggregates, providing in some cases protection against the toxicity of the involved proteins, perhaps by sequestering diffusible toxic species [20], [24][48]; in the long term, this process could contribute to neuronal dysfunction and accelerate neurodegeneration. However, Parkin did not bind to PS129-alpha-synuclein in brain extracts from hA30Palpha-syn mice, and it was unable to promote the ubiquitylation of phosphorylated alpha-synuclein in vitro. It is therefore unlikely that endogenous Parkin contributes to the deposition of PS129-alpha-synuclein through direct mechanisms.
###end p 41
###begin p 42
###xml 459 463 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Trinh1">[49]</xref>
###xml 745 749 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Zeevalk1">[50]</xref>
###xml 849 855 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1074 1080 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1376 1382 1356 1362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1387 1391 1367 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA</italic>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
###xml 423 433 <span type="species:ncbi:7227">Drosophila</span>
###xml 964 968 <span type="species:ncbi:10090">mice</span>
Compensatory mechanisms triggered by Parkin deficiency may intervene indirectly in delaying synucleinopathy and neurodegeneration in hA30Palpha-syn mice. Elevated levels of reduced glutathione have been reported throughout the brain of Parkin-deficient mice. Interestingly, overexpression of genes involved in glutathione biosynthesis and conjugation have each been recently shown to protect against neurodegeneration in a Drosophila model of synucleinopathy [49]. Although the link between increased glutathione levels and decreased alpha-synuclein toxicity in this model remains to be established, it is plausible that increased antioxidant activities associated with the established role of glutathione in protection against oxidative stress [50] affect alpha-synuclein aggregation. It would be valuable to determine the relative contribution of parkin to the molecular pathway leading to accumulation of alpha-synuclein and neurodegeneration in hA30Palpha-syn mice. Current studies in our laboratory aim at evaluating whether and to what extent the deletion of a single parkin allele affects the delay in appearance of signs of motor dysfunction and disease manifestation in this model. These studies should provide useful clues to the mechanisms underlying our current observations; gene dosage-dependent effects would be indicative of direct genetic interaction between parkin and SCNA, whereas their absence would rather hint at compensatory neuroprotective mechanisms triggered by complete but not partial Parkin depletion.
###end p 42
###begin p 43
###xml 335 339 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-vonCoelln1">[51]</xref>
###xml 612 616 592 596 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 886 891 858 863 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 1131 1135 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Conway1">[52]</xref>
###xml 1274 1278 1230 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Martin1">[15]</xref>
###xml 1280 1284 1236 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-vonCoelln1">[51]</xref>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 112 117 <span type="species:ncbi:9606">human</span>
###xml 141 145 <span type="species:ncbi:10090">mice</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 316 320 <span type="species:ncbi:10090">mice</span>
###xml 389 393 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
The effects of Parkin deficiency has been studied in a transgenic mouse model overproducing the A53T variant of human alpha-synuclein. These mice displayed a neurodegenerative phenotype similar to that observed in hA30Palpha-syn mice, but with more severe progression: by 12 months of age, 50% of the hA53Talpha-syn mice were affected [51], whereas at this age, none of the hA30Palpha-syn mice in our study presented features of disease. As in our model, the absence of Parkin did not affect the amount or distribution of native alpha-synuclein, or the appearance of ubiquitin-positive profiles; unfortunately, PS129-alpha-synuclein accumulation was not studied. Although a longitudinal analysis of motor performance in hA53Talpha-syn mice was not provided, the survival curves with and without Parkin were similar. The differences between our results and those described by von Coelln et al may indicate that Parkin deficiency affects A53T and A30P alpha-synucleinopathies differently; Parkin deficiency may have a smaller effect on A53T alpha-synuclein-induced neurodegeneration due to the higher intrinsic aggregation potential [52] and toxicity of A53T alpha-synuclein than A30P alpha-synuclein, leading to a more rapidly progressive neurodegenerative phenotype in mice [15], [51].
###end p 43
###begin p 44
###xml 38 42 34 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-vonCoelln1">[51]</xref>
###xml 187 196 179 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s006">Figure S2</xref>
###xml 198 206 190 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s004">Table S1</xref>
###xml 324 334 316 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s001">Results S1</xref>
###xml 336 346 328 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s005">Figure S1B</xref>
###xml 468 484 456 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">substantia nigra</italic>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
Unfortunately, neither hA53Talpha-syn [51] nor hA30Palpha-syn mice provided evidence for interaction between Parkin deficiency and synucleinopathy in catecholaminergic brainstem neurons (Figure S2, Table S1). This may be due to the weakness of the promoters used to drive transgene expression in these neuronal populations (Results S1, Figure S1B). Therefore, further work with models in which alpha-synuclein accumulates abundantly in the dopaminergic neurons of the substantia nigra, e.g. through viral vector-mediated gene transfer, is required to confirm our findings.
###end p 44
###begin p 45
###xml 328 334 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 449 453 445 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Cookson1">[30]</xref>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
In conclusion, we provide unprecedented evidence that Parkin deficiency modulates the phenotypic expression of disease in a long-term mouse model of synucleinopathy. These findings raise the intriguing possibility that the loss of functional Parkin is a beneficial modifier of alpha-synuclein build-up in the slowly progressive parkin-related parkinsonian syndromes, in which LB pathology is more rarely observed and less severe than in sporadic PD [30].
###end p 45
###begin title 46
Materials and Methods
###end title 46
###begin title 47
Ethics Statement
###end title 47
###begin p 48
###xml 26 30 <span type="species:ncbi:10090">mice</span>
All experiments involving mice were approved by the Ile de France Regional Ethics Committee for Animal Experiments, Ndegrees3 (P3/2006/006).
###end p 48
###begin title 49
###xml 14 29 <span type="species:ncbi:10090">transgenic mice</span>
###xml 44 49 <span type="species:ncbi:9606">human</span>
Generation of transgenic mice overproducing human A30P alpha-synuclein in a Parkin-deficient background
###end title 49
###begin p 50
###xml 207 213 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 235 241 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 247 251 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Itier1">[36]</xref>
###xml 372 376 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Neumann1">[14]</xref>
###xml 378 382 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Kahle1">[37]</xref>
###xml 453 462 445 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g001">Figure 1A</xref>
###xml 476 486 468 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin &#8722;/&#8722;</italic>
###xml 799 800 787 788 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 950 956 932 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1057 1063 1039 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 1071 1073 1053 1055 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 1075 1098 1057 1080 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TGCTCTGGGGTTCGT C-3&#8242;</named-content>
###xml 1101 1103 1083 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">wt</sub>
###xml 1105 1131 1087 1113 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCCACTGGCAGAGTAAATGT-3&#8242;</named-content>
###xml 1176 1178 1158 1160 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sub>
###xml 1180 1206 1162 1188 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTGTTTTGCCAAGTTCTAAT-3&#8242;</named-content>
###xml 1209 1211 1191 1193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KO</sub>
###xml 1213 1237 1195 1219 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">-TCCACTGGCAGAGTAAATGT-3&#8242;</named-content>
###xml 1359 1360 1337 1338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1934 1959 1874 1899 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-AGGGAGCAGGGAGCATTG -3&#8242;</named-content>
###xml 1964 1989 1904 1929 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CAGGATCCACAGGCATATC-3&#8242;</named-content>
###xml 2580 2606 2484 2510 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GAACATCATCCCTGCATCCA-3&#8242;</named-content>
###xml 2614 2639 2518 2543 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CCAGTGAGCTTCCCGTTCA-3&#8242;</named-content>
###xml 2711 2717 2615 2621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 194 199 <span type="species:ncbi:10090">mouse</span>
###xml 229 233 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 487 491 <span type="species:ncbi:10090">mice</span>
###xml 533 537 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
###xml 1910 1915 <span type="species:ncbi:9606">human</span>
###xml 2811 2815 <span type="species:ncbi:10090">mice</span>
Mice transgenic for human A30P alpha-synuclein and deficient for Parkin were generated by a crossbreeding strategy aimed at minimising potential strain effects, using two previously established mouse lines: parkin exon 3-deleted mice (parkin -/-) [36], brought into the C57Bl/6j genetic background by an accelerated backcross procedure; and hA30Palpha-syn mice (line 31H) [14], [37], brought into a C57Bl/6j background by eight consecutive backcrosses (Figure 1A). Homozygous parkin -/- mice were bred with homozygous hA30Palpha-syn mice and mice of the double heterozygous generation were then intercrossed. The progeny of this intercross was genotyped by PCR amplification. Genomic DNA was prepared from tail fragments homogenized in lysis buffer (100 mM Tris-HCl, 0.2% SDS, 200 mM NaCl, 1 mM CaCl2) and digested with proteinase K (10 mg/ml) overnight at 55degreesC; the DNA was precipitated with isopropanol (v/v) and rinsed with 70% ethanol. The parkin genotype was determined by two parallel PCRs using sets of oligonucleotide primers specific for the parkin gene (Fwt: 5'-TGCTCTGGGGTTCGT C-3'; Rwt: 5'-TCCACTGGCAGAGTAAATGT-3') and for the recombinant knock-out allele (FKO: 5'-TTGTTTTGCCAAGTTCTAAT-3'; RKO: -TCCACTGGCAGAGTAAATGT-3'). PCR amplification was carried out in 25 microl reaction mixes containing approximately 300 ng of genomic DNA, 2 mM MgCl2, 0.2 mM dNTPs, 0.4 microM of each oligonucleotide and 1U Taq polymerase (Abscys) in 1X PCR buffer (Abscys). After an initial denaturation step of 3 min at 94degreesC, PCR conditions were: 35 cycles of 94degreesC, 30 s; 58degreesC, 30 s; 72degreesC, 40 s; followed by a 10 min extension at 72degreesC. Semi-quantitative real-time PCR was performed with genomic DNA and an ABI Prism 7700SDS instrument, to determine whether the hA30Palpha-syn transgene was present in the heterozygous or homozygous state. The oligonucleotide pair used to amplify the human transgene was: F: 5'-AGGGAGCAGGGAGCATTG -3'; R: 5'-CAGGATCCACAGGCATATC-3'. The amplification was carried out in reaction volumes of 25 microl consisting of SYBR Green PCR Universal Master Mix (Applied Biosystems) containing 1 ng of DNA and 0.8 microM of each oligonucleotide. The reactions were incubated for 2 min at 50degreesC and for 10 min at 95degreesC, and then amplifications were performed as follows: 40 cycles of 95degreesC, 10 s; 60degreesC, 60 s. Values for the hA30Palpha-syn transgene were normalized to those obtained in the same amplification conditions for the endogenous glyceraldehyde-3-phosphate dehydrogenase gene with the oligonucleotides F: 5'-GAACATCATCCCTGCATCCA-3' and R: 5'-CCAGTGAGCTTCCCGTTCA-3'. Western blotting was used to examine the expression of the endogenous parkin gene and of the hA30Palpha-syn transgene in hemi-brains from four 17 months-old asymptomatic mice per genotype, as described below.
###end p 50
###begin p 51
###xml 415 425 415 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad libitum</italic>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
The frequencies of the nine genotypes of the progeny of the double heterozygous intercross were consistent with Mendelian inheritance. Double homozygous mice and their age-matched littermates of wild-type or single-homozygous, parental genotypes were collected for subsequent analyses. After weaning, male and female mice were separated and maintained at a maximum of five littermates per cage, with food and water ad libitum, and at constant temperature (21degreesC) with a 07:00 - 19:00 light cycle.
###end p 51
###begin title 52
Behavioural analyses
###end title 52
###begin p 53
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 273 277 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
The behaviour of age-matched littermate mice (females) of each selected genotype (n = 10-16) was tested every week, from 9 to 24 months of age. To limit sources of variability, including unnecessary stress, the conditions for testing were kept as constant as possible: the mice were hosted and tested in the same room; the same experimenters (MF and JG), blind to the genotype of the animals throughout the testing period, took care of them and assessed their performance weekly on two consecutive days (Tuesday and Wednesday morning); the tasks were performed in the same order ((i) extension reflex, (ii) rotarod); the between-cage order of testing, initially chosen at random, was kept constant throughout the testing period. Since mice of the same litter were grouped into cages, each cage hosted age-matched animals of different genotypes; the within-cage order of testing was random. Each behavioural session was held during the light period, between 9 a.m. and 12 a.m. and included the two following tests:
###end p 53
###begin p 54
###xml 8 9 8 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8212;</italic>
###xml 157 161 <span type="species:ncbi:10090">Mice</span>
Rotarod - The time spent on a rod (Columbus Instrument) rotating at a speed of 12 rpm was measured. The test was stopped after an arbitrary period of 180 s. Mice falling before the end of this period were tested a second time, and the best trial (longest time) was recorded.
###end p 54
###begin p 55
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8212;</italic>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Barneoud1">[38]</xref>
###xml 28 32 <span type="species:ncbi:10090">Mice</span>
Hindlimb extension reflex - Mice were suspended by their tail and the extension reflex of their hindlimbs was observed. The attribution of arbitrary extension scores was adapted from [38] as follows: 2 for normal extension of both hindlimbs; 1.5 for incomplete extension of one hindlimb; 1 for absence of extension of one hindlimb; 0.5 for absence of extension of one hindlimb and incomplete extension of the second limb; 0 for absence of extension of both hindlimbs.
###end p 55
###begin title 56
###xml 41 49 41 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Western-blot analysis, GST pull-down and in vitro ubiquitylation assays
###end title 56
###begin p 57
###xml 46 50 46 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Kahle2">[53]</xref>
###xml 330 331 327 328 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 333 334 330 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 892 900 873 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g001">Figure 1</xref>
###xml 1164 1168 1133 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1195 1203 1160 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006629-g007">Figure 7</xref>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
###xml 1115 1119 <span type="species:ncbi:10090">mice</span>
Brain extracts were fractionated as described [53]. Briefly, posterior hemi-brains (from bregma -2; approximately 150 mg of frozen tissue) were homogenized in TBS (Tris-buffered saline) containing protease (Complete protease inhibitor cocktail, Roche Diagnostics) and phosphatase (30 mM NaF, 30 mM beta-glycerophosphate, 0.2 mM Na3VO4, 5 mM Na-pyrophosphate and 30 nM okadaic acid) inhibitors. The samples were sonicated, centrifuged at low speed (1,000xg, 5 min, 4degreesC) and ultracentrifuged (130,000xg, 1 h, 4degreesC). The resulting supernatants (the TBS-soluble fractions) were collected. The pellets were extracted twice with 200 microl of TBS containing 5% SDS, and the resulting supernatants were collected and pooled as the TBS-insoluble (SDS-soluble) fraction. Protein concentrations were determined using the bicucullinic acid (BCA) protein assay (Pierce). To confirm genotypes (Figure 1), TBS-soluble brain fractions (10 microg) from non symptomatic 17 months-old mice were analyzed. TBS- and SDS-soluble brain fractions (30 microg) from 17 months-old non symptomatic and 17-25 months-old symptomatic mice were used for assaying alpha-synuclein and PS129-alpha-synuclein proteins (Figure 7).
###end p 57
###begin p 58
###xml 55 59 55 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Hampe1">[26]</xref>
###xml 285 289 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Hampe1">[26]</xref>
###xml 401 409 389 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 434 438 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Paleologou1">[42]</xref>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
GST pull-down assays were done as described previously [26], with 500 microg TBS-soluble brain fraction from a symptomatic mouse, and 5 microg of GST or GST-Parkin immobilized on glutathion-sepharose beads (Amersham Biosciences). Ubiquitylation assays were carried out as described in [26]. Recombinant normal alpha-synuclein and the S87A and S129A variants were produced, purified and phosphorylated in vitro as described previously [42].
###end p 58
###begin p 59
###xml 218 222 218 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
Proteins were resolved by SDS-PAGE on 4-12% gradient gels (Invitrogen). The proteins were electrotransferred onto nitrocellulose membranes and probed with: monoclonal anti-Parkin (MAB5512, clone PRK8, Chemicon), anti PS129-alpha-synuclein (clone PSyn#64, WAKO; clone EP1536Y, Abcam), anti-alpha-tubulin (clone DM 1A, Sigma), anti-FLAG (M2, Sigma); polyclonal anti-alpha-synuclein (SA3400, Affiniti) and anti-actin (A2066, Sigma), anti-GST (GE Healthcare/Amersham). Proteins were visualized by enhanced chemioluminescence (Pierce) using a Kodak Image Station 4000 MM. The Image J program () was used for signal quantification.
###end p 59
###begin title 60
Immunohistochemistry
###end title 60
###begin p 61
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were anaesthetized with pentobarbital (130 mg/kg, i.p.; Sigma, St Quentin, France) and perfused transcardially with 4% paraformaldehyde freshly prepared in 0.1 M PBS, pH 7.4. Brains were removed and post-fixed for two hours in the same solution. Left-half brains were dehydrated by four 10 min incubations and two 20 min incubations in ethanol at 35degreesC, followed by three incubations of 45, 60 and 75 min each in xylene, at 35degreesC. The tissues were then embedded in paraffin by three incubations of 40, 15 and 15 min each at 65degreesC (Shandon Excelsior tissue processor from Thermo Scientific) and cut on a microtome into 5 microm-thick sections collected on slides and stored at room temperature. For immunohistochemistry, sections were deparaffinized in xylene, and hydrated in a descending series of ethanol concentrations. Antigens were retrieved by boiling the sections in 0.01 M citrate buffer, pH 6.0, five times for 3 min in a microwave at 350 Watts.
###end p 61
###begin p 62
###xml 101 102 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 103 104 99 100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 378 382 374 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 976 977 962 963 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 978 979 964 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 425 429 <span type="species:ncbi:9925">goat</span>
###xml 648 654 <span type="species:ncbi:9986">rabbit</span>
###xml 767 778 <span type="species:ncbi:3704">horseradish</span>
For immunoperoxidase staining, sections (5 and 20 microm thick) were incubated in PBS containing 3% H2O2 and 20% ethanol for 5 min, to inhibit endogenous peroxidases. Sections were permeabilized and non specific epitopes were blocked by incubation for 45 min in PBS containing: 2% BSA, 0.1% Triton X-100 (tyrosine-hydroxylase (TH)-staining); 2% NGS, 5% BSA, 0.1% Triton X-100 (PS129-alpha-synuclein staining); or 20% newborn goat serum, 10% BSA, 0.1% Triton X-100 (ubiquitin staining and double immunofluorescent labelling). Sections were hybridized overnight at 4degreesC with the primary antibodies, then treated with biotinylated secondary anti-rabbit IgG antibody (Vectastain; Vector Laboratories, Burlingame, CA, USA), and incubated with avidin and biotinylated horseradish peroxidase complex. The signal was revealed by incubating the sections in 0.25 M Tris-HCl, pH 7.4 containing 0.5% of the peroxidase substrate, 3,3'-diaminobenzidine tetrahydrochloride, and 0.015% H2O2. The sections were dehydrated in an ascending series of ethanol concentrations, cleared in xylene, and mounted with Eukitt Mounting Medium.
###end p 62
###begin p 63
###xml 182 186 <span type="species:ncbi:9925">goat</span>
###xml 192 198 <span type="species:ncbi:9986">rabbit</span>
###xml 248 254 <span type="species:ncbi:9793">donkey</span>
###xml 260 265 <span type="species:ncbi:10090">mouse</span>
For immunofluorescent staining, the sections were then incubated with the primary antibody overnight, at 4degreesC and the signal revealed by incubation with Alexa Fluor 488-coupled goat anti-rabbit IgG antibody (1:2000, Invitrogen) or Cy3-coupled donkey anti-mouse IgG antibody (1:200, Jackson), for one hour at room temperature. The same procedure was used twice sequentially for double stainings. Fluorescent images were acquired with an epifluorescensce microscope (Axioplan 2, Zeiss, Germany) equipped with the FluoUp image analysis system (Explora Nova, La Rochelle, France).
###end p 63
###begin p 64
###xml 49 53 49 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 109 112 105 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006629-Fujiwara1">[1]</xref>
###xml 289 293 285 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 350 354 342 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 431 434 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S87</sup>
###xml 25 31 <span type="species:ncbi:9986">rabbit</span>
###xml 265 271 <span type="species:ncbi:9986">rabbit</span>
###xml 327 332 <span type="species:ncbi:10090">mouse</span>
###xml 477 484 <span type="species:ncbi:9986">rabbits</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
Primary antibodies were: rabbit polyclonal anti-PS129-alpha-synuclein (1:500, kindly provided by T. Iwatsubo [1]); anti-ubiquitin (1:1500, DAKO); anti-synphilin-1 (1:150, kindly provided by Simone Engelender); and anti-activated caspase 9 (1:200, Cell Signalling); rabbit monoclonal anti-PS129-alpha-synuclein (1:5000, Abcam); mouse monoclonal anti-PS129-alpha-synuclein (1:1500, WAKO); and anti-ubiquitin (1:500, Chemicon). Anti-PS87-alpha-synuclein antibodies were raised in rabbits against a peptide identical to residues 81-93 of human alpha-synuclein, with serine 87 being phosphorylated (Eurogentec), and used at a 1:100 dilution.
###end p 64
###begin p 65
###xml 81 105 77 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s002">Materials and Methods S1</xref>
###xml 26 31 <span type="species:ncbi:9606">human</span>
Immunostainings for total human alpha-synuclein and TH were done as described in Materials and Methods S1.
###end p 65
###begin title 66
Quantitative immunohistochemical analyses
###end title 66
###begin p 67
###xml 16 20 16 20 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 725 741 709 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">substantia nigra</italic>
###xml 750 765 734 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">locus coeruleus</italic>
###xml 798 822 782 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s002">Materials and Methods S1</xref>
###xml 830 842 814 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006629.s003">Reference S1</xref>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
The density of PS129-alpha-synuclein immunostaining was evaluated in symptomatic mice (n = 5 per genotype) by determining the mean of eight 5 microm-thick coronal hemi-brain, blind-coded sections, 120 microm apart, covering a brainstem region between bregma -2.5 and -3.5 mm, with a 25xobjective and using the Mercator workstation. The borders of the brainstem area on each section were drawn manually and a grid with counting frames of 150x150 microm was superimposed onto the region of interest. The number of intersections between immunolabelled structures and grid lines was registered for each section. The mean staining density was defined as the average number of intersections per section. TH-positive neurons in the substantia nigra and the locus coeruleus were quantified as described in Materials and Methods S1 and in Reference S1.
###end p 67
###begin p 68
###xml 24 28 24 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 490 494 486 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 841 845 829 833 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1060 1064 1044 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1151 1155 1131 1135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 1401 1405 1377 1381 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 707 711 <span type="species:ncbi:10090">mice</span>
Colocalization between PS129-alpha-synuclein and ubiquitin was analyzed in spinal cord sections processed for double immunofluorescent staining. Images of at least five double-immunostained neurites and five cell bodies from three animals per genotype were taken with a confocal microscope (Leica SP2 AOBS). Colocalization was evaluated with the Pearson's coefficient calculated with the "Colocalization Threshold" plugin of the Java image processing program Image J (). The proportion of PS129-alpha-synuclein-positive cell bodies and neurites immunopositive for ubiquitin was determined from one or two representative double immunofluorescence-labelled, 5 microm-thick brainstem sections from symptomatic mice, chosen between bregma -2.5 and -3.5 mm according to the abundance of immunolabelled structures. To determine the proportion of PS129-alpha-synuclein-positive neurites co-stained with anti-ubiquitin antibodies, fluorescent images were acquired with an epifuorescence microscope (Axioplan 2, Zeiss, Germany), with a filter set for Alexa Fluor 488 (PS129-alpha-synuclein) and a filter set for Cy3 (ubiquitin), and a 63xobjective; 30 to 130 PS129-alpha-synuclein-positive neurites were scored per animal (n = 5 per genotype). To determine the proportion of double-labelled cell bodies, brain sections were examined directly with the epifluorescent microscope and the 63xobjective; 30 to 200 PS129-alpha-synuclein-positive cell bodies were scored per animal (n = 4 per genotype).
###end p 68
###begin p 69
###xml 19 23 19 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 187 191 183 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 410 414 402 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 594 598 <span type="species:ncbi:10090">mice</span>
###xml 650 654 <span type="species:ncbi:10090">mice</span>
The percentage of PS129-alpha-synuclein- or ubiquitin-positive neurons double stained for cleaved caspase 9, and the percentage of neurons accumulating cleaved caspase 9 co-labelled for PS129-alpha-synuclein or ubiquitin was estimated throughout the spinal cord of symptomatic mice. Sections were examined directly with the epifluorescent microscope and the 63xobjective; 140 to 660 neuronal cell bodies with PS129-alpha-synuclein, and 30 to 330 with ubiquitin staining were scored per animal (n = 4 per genotype). Seventy neurons with cleaved caspase 9 staining were scored for hA30Palpha-syn mice without Parkin (n = 4), and 150 for hA30Palpha-syn mice with Parkin (n = 4).
###end p 69
###begin title 70
Statistical analyses
###end title 70
###begin p 71
Values from behavioural studies were analyzed using second-order polynomial curve fitting of mean performance against age, and ANOVA comparison of the corresponding regression curve parameters (slope and curvature), with genotype as qualitative factor. The regression equations were:
###end p 71
###begin p 72
###xml 343 347 343 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 572 576 564 568 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S129</sup>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
Unpaired t-tests were used to estimate differences in disease progression between groups. Data from quantitative western blots were analyzed using two-way ANOVA, followed by the Student-Newman-Keuls Method for pairwise multiple comparisons, as appropriate. An unpaired two-tailed t-test was used to estimate differences in the percentages of PS129-alpha-synuclein- or ubiquitin-positive neurons with cleaved caspase 9 staining between symptomatic hA30Palpha-syn littermate mice with and without Parkin. An unpaired one-tailed t-test was used to analyse the proportion of PS129-alpha-synuclein-positive structures co-labelled with anti-ubiquitin antibodies.
###end p 72
###begin title 73
Supporting Information
###end title 73
###begin p 74
(0.03 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
(0.03 MB DOC)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
(0.02 MB DOC)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
(0.03 MB DOC)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
###xml 100 104 <span type="species:ncbi:10090">mice</span>
###xml 177 182 <span type="species:ncbi:9606">human</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 323 327 <span type="species:ncbi:10090">mice</span>
###xml 813 817 <span type="species:ncbi:10090">mice</span>
###xml 867 872 <span type="species:ncbi:9606">human</span>
###xml 951 956 <span type="species:ncbi:9606">human</span>
Thy-1-driven expression of the hA30PI+/--syn transgene throughout the brain and spinal cord of aged mice. A, Representative micrographs showing immunohistochemical labelling of human I+/--synuclein in various brain and spinal cord regions from healthy hA30PI+/--syn 17 months-old mice (a-f), and from end-stage symptomatic mice presenting pathological profiles (arrows) (g-i). Both typical, dotted synaptic labelling and staining of the somatodendritic compartment were observed. Similar results were obtained in the presence or absence of Parkin. Scale bar: 100 I(1/4)m. B, I+/--Synuclein immunoreactivity is absent from the cell bodies of monoaminergic neurons of the substantia nigra and the locus coeruleus. Representative micrographs of confocal laser-scanned brain sections from 17 months-old hA30PI+/--syn mice, immunolabelled by double fluorescence with anti-human I+/--synuclein and anti-TH antibodies. Arrows and arrowheads indicate TH- and human I+/--synuclein-immunopositive neurons, respectively. Similar results were obtained in the presence and absence of Parkin. Scale bar: 50 Amum.
###end p 82
###begin p 83
(11.19 MB TIF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
###xml 117 121 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
Parkin deficiency does not affect the survival of the dopaminergic neurons of the SNc in 17 months-old hA30PI+/--syn mice. A, Micrographs illustrating TH-immunoreactivity in the substantia nigra of mice representative of each genotype. B, Stereological quantification of TH-positive neurons in the substantia nigra pars compacta (n = 4). Data presented are means+/-SEM. Scale bar: 100 Amum.
###end p 85
###begin p 86
(6.69 MB TIF)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
###xml 268 274 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">parkin</italic>
We thank S. Engelender (Technion-Israel Institute of Technology, Haifa, Israel) for kindly providing anti-synphilin-1 antibodies; P. Barneoud (Sanofi-Aventis, Vitry, France) for excellent advice on behavioural assessments; Sanofi-Aventis (Vitry, France) for providing parkin -/- breeder pairs.
###end p 88
###begin title 89
References
###end title 89
###begin article-title 90
alpha-Synuclein is phosphorylated in synucleinopathy lesions.
###end article-title 90
###begin article-title 91
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.
###end article-title 91
###begin article-title 92
Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.
###end article-title 92
###begin article-title 93
Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
###end article-title 93
###begin article-title 94
Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin.
###end article-title 94
###begin article-title 95
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease.
###end article-title 95
###begin article-title 96
Parkinson's disease and dementia with Lewy bodies: a difference in dose?
###end article-title 96
###begin article-title 97
Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication.
###end article-title 97
###begin article-title 98
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 85 90 <span type="species:ncbi:9606">human</span>
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
###end article-title 98
###begin article-title 99
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 34 39 <span type="species:ncbi:9606">human</span>
Neuropathology in mice expressing human alpha-synuclein.
###end article-title 99
###begin article-title 100
###xml 2 12 <span type="species:ncbi:7227">Drosophila</span>
A Drosophila model of Parkinson's disease.
###end article-title 100
###begin article-title 101
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 161 176 <span type="species:ncbi:10090">transgenic mice</span>
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
###end article-title 102
###begin article-title 103
###xml 77 92 <span type="species:ncbi:10090">transgenic mice</span>
###xml 129 134 <span type="species:ncbi:9606">human</span>
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
###end article-title 103
###begin article-title 104
###xml 36 51 <span type="species:ncbi:10090">transgenic mice</span>
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death.
###end article-title 104
###begin article-title 105
Alpha-synuclein dysfunction in Lewy body diseases.
###end article-title 105
###begin article-title 106
Of Parkin and Parkinson's: light and dark sides of a multifaceted E3 ubiquitin-protein ligase.
###end article-title 106
###begin article-title 107
Parkinson disease(s). Is "Parkin disease" a distinct clinical entity?
###end article-title 107
###begin article-title 108
How much phenotypic variation can be attributed to parkin genotype?
###end article-title 108
###begin article-title 109
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells.
###end article-title 109
###begin article-title 110
Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling.
###end article-title 110
###begin article-title 111
A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling.
###end article-title 111
###begin article-title 112
Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels.
###end article-title 112
###begin article-title 113
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.
###end article-title 113
###begin article-title 114
Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro.
###end article-title 114
###begin article-title 115
Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity.
###end article-title 115
###begin article-title 116
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age.
###end article-title 116
###begin article-title 117
Dopamine covalently modifies and functionally inactivates parkin.
###end article-title 117
###begin article-title 118
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
###end article-title 118
###begin article-title 119
Genetic neuropathology of Parkinson's disease.
###end article-title 119
###begin article-title 120
Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
###end article-title 120
###begin article-title 121
###xml 83 93 <span type="species:ncbi:7227">Drosophila</span>
Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila.
###end article-title 121
###begin article-title 122
###xml 33 43 <span type="species:ncbi:7227">Drosophila</span>
parkin counteracts symptoms in a Drosophila model of Parkinson's disease.
###end article-title 122
###begin article-title 123
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons.
###end article-title 123
###begin article-title 124
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
###end article-title 124
###begin article-title 125
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse.
###end article-title 125
###begin article-title 126
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 121 126 <span type="species:ncbi:10090">mouse</span>
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
###end article-title 126
###begin article-title 127
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Quantitative motor assessment in FALS mice: a longitudinal study.
###end article-title 127
###begin article-title 128
###xml 74 89 <span type="species:ncbi:10090">transgenic mice</span>
Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice.
###end article-title 128
###begin article-title 129
###xml 84 94 <span type="species:ncbi:7227">Drosophila</span>
Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.
###end article-title 129
###begin article-title 130
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 96 99 <span type="species:ncbi:10116">rat</span>
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
###end article-title 130
###begin article-title 131
Phosphorylation at S129, but not the phosphomimics S129E/D inhibits the fibrilization of alpha -synuclein.
###end article-title 131
###begin article-title 132
Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death.
###end article-title 132
###begin article-title 133
###xml 98 101 <span type="species:ncbi:10116">rat</span>
Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.
###end article-title 133
###begin article-title 134
###xml 37 40 <span type="species:ncbi:10116">rat</span>
Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
###end article-title 134
###begin article-title 135
Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein.
###end article-title 135
###begin article-title 136
Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.
###end article-title 136
###begin article-title 137
The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration.
###end article-title 137
###begin article-title 138
###xml 75 85 <span type="species:ncbi:7227">Drosophila</span>
Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease.
###end article-title 138
###begin article-title 139
###xml 49 57 <span type="species:ncbi:99490|species:ncbi:9783|species:ncbi:9785">elephant</span>
Glutathione and Parkinson's disease: is this the elephant in the room?
###end article-title 139
###begin article-title 140
###xml 75 80 <span type="species:ncbi:10090">mouse</span>
Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
###end article-title 140
###begin article-title 141
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy.
###end article-title 141
###begin article-title 142
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:10090">mouse</span>
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
###end article-title 142
###begin article-title 143
Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
###end article-title 143
###begin p 144
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 144
###begin p 145
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Margot Fournier was supported by the French Ministry of Research and the Fondation pour la Recherche Medicale. This project was supported by Institut National de la Sante et de la Recherche Medicale, Abnormal proteins in the pathogenesis of neurodegenerative disorders (APOPIS, an integrated project funded by the EU under the Sixth Framework Programme; Priority: Life Science for Health, contract no. LSHM-CT-2003-503330), Fondation de France (2003 013 796), and Federation pour la Recherche sur le Cerveau. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 145

